- Home
- AKTX vs FLUX Comparison
AKTX vs FLUX Comparison
Compare AKTX & FLUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKTX
- FLUX
- Stock Information
- Founded
- AKTX N/A
- FLUX N/A
- Country
- AKTX United States
- FLUX United States
- Employees
- AKTX N/A
- FLUX N/A
- Industry
- AKTX Biotechnology: Pharmaceutical Preparations
- FLUX Industrial Machinery/Components
- Sector
- AKTX Health Care
- FLUX Miscellaneous
- Exchange
- AKTX Nasdaq
- FLUX Nasdaq
- Market Cap
- AKTX 37.2M
- FLUX 25.4M
- IPO Year
- AKTX N/A
- FLUX N/A
- Fundamental
- Price
- AKTX $1.14
- FLUX $1.90
- Analyst Decision
- AKTX
- FLUX Strong Buy
- Analyst Count
- AKTX 0
- FLUX 2
- Target Price
- AKTX N/A
- FLUX $6.00
- AVG Volume (30 Days)
- AKTX 26.9K
- FLUX 132.4K
- Earning Date
- AKTX 08-18-2025
- FLUX 08-15-2025
- Dividend Yield
- AKTX N/A
- FLUX N/A
- EPS Growth
- AKTX N/A
- FLUX N/A
- EPS
- AKTX N/A
- FLUX N/A
- Revenue
- AKTX N/A
- FLUX $63,074,000.00
- Revenue This Year
- AKTX N/A
- FLUX $11.10
- Revenue Next Year
- AKTX N/A
- FLUX $12.66
- P/E Ratio
- AKTX N/A
- FLUX N/A
- Revenue Growth
- AKTX N/A
- FLUX N/A
- 52 Week Low
- AKTX $0.85
- FLUX $1.15
- 52 Week High
- AKTX $4.40
- FLUX $4.75
- Technical
- Relative Strength Index (RSI)
- AKTX 43.82
- FLUX 58.26
- Support Level
- AKTX $1.10
- FLUX $1.36
- Resistance Level
- AKTX $1.18
- FLUX $2.53
- Average True Range (ATR)
- AKTX 0.05
- FLUX 0.20
- MACD
- AKTX 0.00
- FLUX 0.06
- Stochastic Oscillator
- AKTX 39.52
- FLUX 52.14
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.
About FLUX Flux Power Holdings Inc.
Flux Power Holdings Inc design, develop, manufacture, and sell a portfolio of lithium-ion energy storage solutions for electrification of a range of industrial commercial sectors which include material handling, airport ground support equipment (GSE), and other commercial and industrial applications. It offers a high-power battery cell management system(BMS). The company's BMS provides three functions to its battery systems which include Cell Balancing, Monitoring, and Error Reporting.